Zacks.com on MSN16d
Lilly's Zepbound Receives FDA Approval for Sleep Apnea
FDA approves LLY's obesity drug Zepbound for its second indication, moderate-to-severe obstructive sleep apnea.
Nasdaq16d
Lilly's Zepbound Receives FDA Approval for Sleep Apnea
Also, rival Novo Nordisk NVO announced disappointing data ... which showed that patients not on positive airway pressure (PAP) therapy taking Zepbound experienced 25 fewer breathing disruptions ...
Becker's ASC24d
GLP-1s driving up healthcare usage: 5 things to know
The rising use of GLP-1 medications, such as Novo Nordisk's Wegovy and Ozempic ... an uptick in GLP-1 use is facilitating a range of "crucial preventive care," including pap smears and colonoscopies.
STAT5d
They may be ‘miracle’ drugs, but obesity meds call for a team approach
The explosive rise of GLP-1 drugs like Ozempic has brought an accompanying challenge: logistics too knotty for a single ...
CNBC on MSN19d
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance coverage for the treatment.
The popular weight-loss drug Zepbound can now be used to treat sleep apnea
The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity.
Lilly Rises on FDA Approval of Weight-Loss Drug Zepbound for Sleep Apnea
Eli Lilly stock rose Monday after Zepbound received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea among adults with obesity.